I would like to say to the Commissioner that it is undoubtedly a fact that the current system of dealing with variations in the terms of marketing authorisations for medicinal products is unsatisfactory and, in many cases, works against the interests both of the pharmaceutical industry, but also – most importantly – of the patients themselves. It is therefore essential that the revision should be conducted.
Je voudrais dire au Commissaire qu’il est indiscutable que le système actuel de gestion des conditions de mise sur le marché des médicaments n’est pas satisfaisant, et qu’il est souvent contraire aux intérêts de l’industrie pharmaceutique mais aussi, et surtout, des patients eux-mêmes. Il est donc essentiel de le réviser.